# EDGAR Filing Document

**Accession Number:** 0001819257
**File Stem:** 0001104659-25-076677
**Filing Date:** 2025-8
**Character Count:** 5334
**Document Hash:** 783cb9d85485fddc3d6522f483134a04
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-076677.hdr.sgml**: 20250812

**ACCESSION NUMBER**: 0001104659-25-076677

**CONFORMED SUBMISSION TYPE**: N-PX

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250812

**EFFECTIVENESS DATE**: 20250812

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Patient Square Capital LP
- **CENTRAL INDEX KEY:** 0001819257

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** N-PX
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 028-22927
- **FILM NUMBER:** 251205435

**BUSINESS ADDRESS:**
- **STREET 1:** 2884 SAND HILL ROAD, SUITE 100
- **CITY:** MENLO PARK
- **STATE:** CA
- **ZIP:** 94025
- **BUSINESS PHONE:** 212-446-4600

**MAIL ADDRESS:**
- **STREET 1:** 2884 SAND HILL ROAD, SUITE 100
- **CITY:** MENLO PARK
- **STATE:** CA
- **ZIP:** 94025

## FORM N-PX
### ANNUAL REPORT OF PROXY VOTING RECORD

## N-PX: Filer Information

**Filer CIK:** 0001819257

**Date of Report:** 06/30/2025

**Are you a Registered Management Investment Company or an Institutional Manager?:** Institutional Manager

**Is this a LIVE or TEST Filing?:** LIVE

**Is this an electronic copy of an official filing submitted in paper format?:** [ ]

### Submission Contact Information
_Not provided in this filing._

### Notification Information
**Notify via Filing Website only?:** [ ]

## N-PX: Cover Page

**Name of reporting person:** Patient Square Capital LP

**Address:** 2884 SAND HILL ROAD, SUITE 100, MENLO PARK, CA 94025

**Telephone number:** 650-677-8100

**Name of agent for service:** —

**Agent Address:** —, —, — —

**Reporting Period:** Report for the year ended 06/30/2025

**SEC File Number:** 028-22927

**CRD Number (if any):** —

**Other SEC File Number (if any):** —

**LEI (if any):** 254900OCHZT9EZWLI955

**Report Type (check only one):**

Institutional Manager.

- [x] Institutional Manager Voting Report

- [ ] Institutional Manager Notice Report

- [ ] Institutional Manager Combination Report

Registered Management Investment Company.

- [ ] Fund Voting Report

- [ ] Fund Notice Report

**Do you wish to provide explanatory information pursuant to Special Instruction B.4?:**

- [x] No

- [ ] Yes

**Additional information:** —

## N-PX: Summary - Included Managers

**Number of Included Institutional Managers:** 0

**Included Institutional Managers:** —

## FORM N-PX PROXY VOTING RECORD

| NAME OF ISSUER                 | CUSIP     | MEETING DATE   | VOTE DESCRIPTION                                                                                                                                                                                        | VOTE CATEGORY                |   SHARES VOTED |   SHARES ON LOAN | HOW VOTED   |   SHARES VOTED FOR OR AGAINST MANAGEMENT | FOR OR AGAINST MANAGEMENT   | OTHER INFO   |
|:---|:---|:---|:---|:---|---:|---:|:---|---:|:---|:---|
| EYEPOINT PHARMACEUTICALS, INC. | 30233G209 | 06/18/2025     | Election of Directors: Goran Ando, M.D.; Jay S. Duker, M.D.; Nancy Lurker; John B. Landis, Ph.D.; Wendy DiCicco; Karen Zaderej; Stuart Duty; Fred Hassan; Reginald Sanders, M.D.                        | DIRECTOR ELECTIONS           |        1481977 |                0 | FOR         |                                  1481977 | FOR                         |  |
| EYEPOINT PHARMACEUTICALS, INC. | 30233G209 | 06/18/2025     | To approve Amendment No. 2 to the Eyepoint Pharmaceuticals, Inc. 2023 Long-Term Incentive Plan to increase the number of shares of common stock authorized for issuance thereunder by 2,900,000 shares. | CAPITAL STRUCTURE            |        1481977 |                0 | FOR         |                                  1481977 | FOR                         |  |
| EYEPOINT PHARMACEUTICALS, INC. | 30233G209 | 06/18/2025     | To approve, on an advisory basis, the compensation paid to the Company's named executive officers as disclosed in the accompanying proxy statement.                                                     | SECTION 14A SAY-ON-PAY VOTES |        1481977 |                0 | FOR         |                                  1481977 | FOR                         |  |
| EYEPOINT PHARMACEUTICALS, INC. | 30233G209 | 06/18/2025     | To vote, on an advisory basis, on the frequency of advisory stockholder votes on the compensation paid to our named executive officers.                                                                 | SECTION 14A SAY-ON-PAY VOTES |        1481977 |                0 | FOR         |                                  1481977 | FOR                         |  |
| EYEPOINT PHARMACEUTICALS, INC. | 30233G209 | 06/18/2025     | To ratify the appointment of Deloitte  Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.                                          | AUDIT-RELATED                |        1481977 |                0 | FOR         |                                  1481977 | FOR                         |  |

## N-PX: Signature Block

**Reporting Person:** Patient Square Capital LP

**By (Signature):** Carolyn Drayer-Greenwalt

**By (Printed Signature):** Carolyn Drayer-Greenwalt

**By (Title):** Chief Compliance Officer

**Date:** 08/04/2025